Parliament Workbench
Data: Motions & questions to 19 Nov 2026

Written Question · S5W-20773 · Session 5

What its position is on allowing interim access to the cystic fibrosis treatment, Orkambi, through the Cystic Fibrosis Trust’s clinical dat…

Answered Asked by Alex Cole-Hamilton LD Lodged 20 Dec 2018

The question

To ask the Scottish Government what its position is on allowing interim access to the cystic fibrosis treatment, Orkambi, through the Cystic Fibrosis Trust’s clinical data registry.

The answer

Answered by Jeane Freeman on 8 Jan 2019 · 19 days after it was lodged, on time

There is an established process for licensed medicines to be appraised through the Scottish Medicines Consortium and we expect companies to follow this route. I am pleased that Vertex Pharmaceuticals have announced that it will make a new submission to the SMC for Orkambi.
Meantime, PACS Tier Two allows clinicians to apply for individual patient access to medicines which would otherwise be routinely unavailable to them, such as Orkambi. I welcome Vertex’s commitment to make Orkambi available to the NHS through PACS Tier Two at a discounted price and would strongly encourage clinicians to make use of this system if they judge this medicine as appropriate for their individual patient’s needs.

In the Official Report

No contribution in the Official Report cites S5W-20773 by reference.